Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to explore trends in safety and efficacy, and to find the
optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial
will depend on both safety (incidence of symptomatic intracranial hemorrhage) and efficacy
(reperfusion measured by MRI and correlating with clinical outcome) profiles. The safety
(incidence of symptomatic intracranial haemorrhage) and efficacy (reperfusion measured by MRI
and correlating with clinical outcome) profiles gained from this study were the basis of
planning the phase III.